Effect of zoledronic acid therapy on postmenopausal osteoporosis between the Uighur and Han population in Xinjiang: An open-label, long-term safety and efficacy study

2017 ◽  
Vol 43 (3) ◽  
pp. 336-341
Author(s):  
W. Xu ◽  
C. Xiang ◽  
H. Wang ◽  
H. Yuan ◽  
X. Zhao ◽  
...  
2005 ◽  
Vol 00 (00) ◽  
pp. 1
Author(s):  
Fred Saad ◽  

Men with advanced prostate cancer are at high risk for development of bone metastases,resulting in clinically significant skeletal morbidity and severe bone pain. Studies of early-generation bisphosphonates,clodronate, and pamidronate,demonstrated transient palliative effects on bone pain in patients with bone metastases, but failed to demonstrate long-term clinical benefit.A small,open-label study of ibandronate demonstrated significant reductions in pain,but these results have not been confirmed in a larger,randomized,controlled trial. Currently,zoledronic acid is the only bisphosphonate that has demonstrated statistically significant reductions in skeletal morbidity – including durable pain reduction– in this patient population in a randomized placebocontrolled trial.Therefore,zoledronic acid therapy should be considered to prevent skeletal morbidity and improve the quality of life of prostate cancer patients with bone metastases.


Epilepsia ◽  
2021 ◽  
Author(s):  
Anup D. Patel ◽  
Maria Mazurkiewicz‐Bełdzińska ◽  
Richard F. Chin ◽  
Antonio Gil‐Nagel ◽  
Boudewijn Gunning ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document